Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anasuya Hazra

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|February 1, 2024
Tofacitinib pharmacokinetics in children and adolescents with juvenile idiopathic arthritisCheng Chang, Camille Vong, Xiaoxing Wang, et al.
Advances in Therapy|February 27, 2025
Population Pharmacokinetics of Niraparib/Abiraterone Acetate Administered as Single-Agent Combination and Dual-Acting Tablets Plus Prednisone for Metastatic Castration-Resistant Prostate CancerAlberto Russu, Anasuya Hazra, Hui Tian, et al.
Journal of Clinical Pharmacology|December 16, 2014
Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney diseaseMichael A Tortorici, David L Cutler, Anasuya Hazra, et al.
British Journal of Clinical Pharmacology|January 30, 2018
Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trialArnab Mukherjee, Anasuya Hazra, Mike K Smith, et al.
British Journal of Pharmacology|May 19, 2021
Translational PK/PD and model-informed development of JNJ-67842125, a F<sub>ab</sub> reversal agent for JNJ-64179375, a long-acting thrombin inhibitorVivaswath S Ayyar, Pharavee Jaiprasart, Brian Geist, et al.
Clinical Pharmacokinetics|March 4, 2024
Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and SimulationAlex Yu, Anasuya Hazra, James Juhui Jiao, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 15, 2018
Evaluation of the Short-, Mid-, and Long-Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid ArthritisRonald van Vollenhoven, Eun Bong Lee, Sander Strengholt, et al.
Cancer Chemotherapy and Pharmacology|March 23, 2021
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)Fred Saad, Kim N Chi, Neal D Shore, et al.
Clinical Immunology (Orlando, Fla.)|March 9, 2018
Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteersKent J Weinhold, Jack F Bukowski, Todd V Brennan, et al.
Pediatric Rheumatology Online Journal|December 29, 2017
Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter studyNicolino Ruperto, Hermine I Brunner, Zbigniew Zuber, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
CPT: Pharmacometrics & Systems Pharmacology|February 1, 2024
Tofacitinib pharmacokinetics in children and adolescents with juvenile idiopathic arthritisCheng Chang, Camille Vong, Xiaoxing Wang, et al.
Advances in Therapy|February 27, 2025
Population Pharmacokinetics of Niraparib/Abiraterone Acetate Administered as Single-Agent Combination and Dual-Acting Tablets Plus Prednisone for Metastatic Castration-Resistant Prostate CancerAlberto Russu, Anasuya Hazra, Hui Tian, et al.
Journal of Clinical Pharmacology|December 16, 2014
Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney diseaseMichael A Tortorici, David L Cutler, Anasuya Hazra, et al.
British Journal of Clinical Pharmacology|January 30, 2018
Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trialArnab Mukherjee, Anasuya Hazra, Mike K Smith, et al.
British Journal of Pharmacology|May 19, 2021
Translational PK/PD and model-informed development of JNJ-67842125, a F<sub>ab</sub> reversal agent for JNJ-64179375, a long-acting thrombin inhibitorVivaswath S Ayyar, Pharavee Jaiprasart, Brian Geist, et al.
Clinical Pharmacokinetics|March 4, 2024
Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and SimulationAlex Yu, Anasuya Hazra, James Juhui Jiao, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 15, 2018
Evaluation of the Short-, Mid-, and Long-Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid ArthritisRonald van Vollenhoven, Eun Bong Lee, Sander Strengholt, et al.
Cancer Chemotherapy and Pharmacology|March 23, 2021
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)Fred Saad, Kim N Chi, Neal D Shore, et al.
Clinical Immunology (Orlando, Fla.)|March 9, 2018
Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteersKent J Weinhold, Jack F Bukowski, Todd V Brennan, et al.
Pediatric Rheumatology Online Journal|December 29, 2017
Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter studyNicolino Ruperto, Hermine I Brunner, Zbigniew Zuber, et al.
Pageof 3